BFM
CGON icon

Boothbay Fund Management’s CG Oncology CGON Stock Holding History

Boothbay Fund Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-228,900
Closed -$15.5M – 2290
2026
Q1 		$15.5M Buy
+228,900
New +$13M 0.2% 63

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's CGON Position: Q1 2026 in Review

Boothbay Fund Management sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 59,400 shares — an estimated $3.37M sold.

Boothbay Fund Management first reported a position in CGON in Q2 2025 and held it in 3 quarters. The position peaked at $3.81M in Q3 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Boothbay Fund Management reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 59,400 CG Oncology shares in Q1 2026, an estimated $3.37M.
  • Boothbay Fund Management first reported a position in CG Oncology in Q2 2025 and held it in 3 quarters.
  • Boothbay Fund Management's CG Oncology position peaked at $3.81M in Q3 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.